Clinical trials: Diabetes Mellitus Type II,
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens
Diabetes Mellitus, Type 2
An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
This is an open-label single-arm observational trial to study the effectiveness of a commercially available meal-replacement shake and its effect on the quality of life in individuals with type 2 diabetes.
- Trial name
- NCT05129735
- Testing
- Meal replacement shake
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Teatis, Inc
Diabetes Type 2
Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
The aim of the study is to compare the effects of aerobic interval training and the IDF recommendations on physical activity on cardiac function and CV risk factors in patients with diabetes.
- Trial name
- NCT01206725
- Testing
- Exercise
- Where
- Norway
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Incretin Effect
Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes
Patients with T2DM lac a sufficient incretin response after oral glucose intake. It has only been tested using 50g of glucose. We don't know if patients with T2DM are capable of regulating the incretin effect like healthy people…
- Trial name
- NCT00529048
- Testing
- Oral Glucose Tolerance Test, Isoglycemic clamp, Gastric emptying rate
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Diabetes Mellitus, Type 2
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic…
- Trial name
- NCT00690755
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients
Abstract Diabetes mellitus and periodontal diseases are both chronic inflammatory disorders that have a major impact on the health and well being of millions of individuals worldwide.
- Trial name
- NCT01475435
- Testing
- non- surgical periodontal treatment, Prophylaxis
- Where
- Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Diabetes Mellitus, Type 2
MBCT for DM Distress: a Pilot Qusai-experimental Study
Background: Diabetes-related distress (DRD) is very common among people with type II diabetes mellitus (DM). DRD led to poorer DM control and may led to adverse prognosis.
- Trial name
- NCT03484689
- Testing
- Mindfulness-based cognitive therapy MBCT
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Diabetes Mellitus, Type 2, Insomnia
The Impact of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Glycemic Control in Older Type 2 Diabetes (T2D) Comorbid With Insomnia
This study is a RCT aiming to use CBT-I as intervention, compared to usual care as control, to elucidate the effect of CBT-I on glycemic control, sleep quality, psychological outcomes, and cognitive function in Hong Kong Chinese…
- Trial name
- NCT04831385
- Testing
- Cognitive Behavioural Therapy
- Where
- Hong Kong
- Volunteers
- 214 people
- Sponsor
- Chinese University of Hong Kong
Latent Tuberculosis Infection
Latent Tuberculosis in Type 2 Diabetes
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated.
- Trial name
- TB (NCT06874725)
- Testing
- Rifapentine and Isoniazid for 3 months, Isoniazid (INH) daily for 9 months
- Where
- Taiwan
- Volunteers
- 552 people
- Sponsor
- Taichung Veterans General Hospital
Type 2 Diabetes
Beneficial Effects of Quinoa (Chenopodium Quinoa Willd) in the Prevention of Type 2 Diabetes Mellitus
Quinoa is a pseudo-cereal and has potential health benefits and exceptional nutritional value. It is a food rich in proteins of high biological value, in unsaturated fats and fiber, it is also a grain low in carbohydrates and…
- Trial name
- NCT04529317
- Testing
- Quinoa and quinoa-based food
- Where
- Spain
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
Type 2 Diabetes, Obesity
The Medically Reproducing Bariatric Surgery (MRB) II Study
Roux-en-Y (RYGB) gastric bypass reduces the size and capacity of the stomach and bypasses a portion of the small intestine which leads to decreased food intake and higher levels of a gut hormone called GLP-1…
- Trial name
- NCT06363747
- Testing
- Very Low Calorie Diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Durham VA Medical Center
Psoriatic Arthritis, Osteoarthitis
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance…
- Conditions
- Psoriatic Arthritis, Osteoarthitis, Knee, Diabetes (DM)
- Trial name
- CARTIZ (NCT07567378)
- Testing
- Tirzepatide
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- JULIO GRANADOS MONTIEL
Type 2 Diabetes Mellitus
A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years
The use of dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon like peptide 1 (GLP1) analogues for the treatment of diabetic mellitus (DM) type 2 is growing (1,2).
- Trial name
- NCT01681550
- Testing
- Incretin-based therapy
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Nagaoka Red Cross Hospital
Diabetes in Adolescence, Type 2 Diabetes
Pilot-Testing Strategies to Improve Outcomes for Youth With Type 2 Diabetes by Addressing Health-Related Social Needs
The goal of this clinical trial is to pilot test different strategies to address health related social needs (HRSN) experienced by adolescent and young adult patients with type 2 diabetes and their families.
- Conditions
- Diabetes in Adolescence, Type 2 Diabetes, Social Needs
- Trial name
- ONWARD (NCT07216118)
- Testing
- Tailored Resources, Universal Empowerment, Text Messages
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Peripheral Arterial Disease, Type II Diabetes Mellitus
Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
The hypothesis of this proposal is that in subjects with Type II diabetes mellitus (T2D) and peripheral arterial disease (PAD) with intermittent claudication (IC), regular consumption of a high nitrate supplement which raises…
- Trial name
- DM+PAD (NCT01785524)
- Testing
- Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.